Medexus Pharmaceuticals Inc.

TSX:MDP Voorraadrapport

Marktkapitalisatie: CA$53.0m

Medexus Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Medexus Pharmaceuticals is Ken d'Entremont, benoemd in Dec2018, heeft een ambtstermijn van 5.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.11M, bestaande uit 46.8% salaris en 53.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.99% van de aandelen van het bedrijf, ter waarde CA$ 3.18M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 6.1 jaar.

Belangrijke informatie

Ken d'Entremont

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris46.8%
Dienstverband CEO5.9yrs
Eigendom CEO6.0%
Management gemiddelde ambtstermijn4.5yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Analyse CEO-vergoeding

Hoe is Ken d'Entremont's beloning veranderd ten opzichte van Medexus Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$2m

Jun 30 2024n/an/a

US$1m

Mar 31 2024US$1mUS$517k

-US$214k

Dec 31 2023n/an/a

US$6m

Sep 30 2023n/an/a

US$5m

Jun 30 2023n/an/a

US$3m

Mar 31 2023US$882kUS$400k

US$1m

Dec 31 2022n/an/a

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

US$2m

Mar 31 2022US$592kUS$400k

-US$3m

Dec 31 2021n/an/a

-US$8m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021US$688kUS$328k

-US$28m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020US$385kUS$300k

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019US$2mUS$144k

-US$5m

Compensatie versus markt: De totale vergoeding ($USD 1.11M ) Ken } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 169.37K ).

Compensatie versus inkomsten: De beloning van Ken is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Ken d'Entremont

5.9yrs

Tenure

US$1,106,271

Compensatie

Mr. Kenneth d'Entremont, also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 17,2018 and served as its Chief Operating Officer sinc...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kenneth d'Entremont
CEO & Director5.9yrsUS$1.11m5.99%
CA$ 3.2m
Richard Labelle
Chief Operating Officerno dataUS$374.12k0.093%
CA$ 49.3k
Ian Wildgoose Brown
General Counsel & Corporate Secretary3yrsUS$446.08k0.084%
CA$ 44.4k
Brendon Buschman
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Tina Byers
Executive of Investor Relationsno datageen gegevensgeen gegevens
Bill Poncy
Senior Vice President of Commercial Operations - United States6.1yrsUS$439.69kgeen gegevens
Brian Peters
Vice President of Sales & Marketing - United Statesno dataUS$281.91kgeen gegevens

4.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van MDP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Kenneth d'Entremont
CEO & Director6.1yrsUS$1.11m5.99%
CA$ 3.2m
Michael Mueller
Independent Chairman10.5yrsUS$94.71k0.39%
CA$ 208.7k
Benoit Gravel
Independent Director7.2yrsUS$83.38k0.26%
CA$ 136.6k
Stephen Nelson
Independent Director6.1yrsUS$73.94k2.25%
CA$ 1.2m
Nancy Phelan
Independent Director1.2yrsUS$39.27k0.045%
CA$ 24.0k
Harmony Garges
Independent Director1.8yrsUS$62.92k0.099%
CA$ 52.5k
Menassie Taddese
Independent Director1.8yrsUS$66.90k0.099%
CA$ 52.5k

6.1yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MDP wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).